TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
PARIS, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 will be available from January 2023. SymbioLife® Satylia® is a precision probiotic with a characterized mechanism of...
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dated September 9, 2022 jointly submitted by Dr. Gang Yu, co-founder and co-chairman of the Company, Mr....
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, Dec. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and Xuanzhu Biopharma, today announce that they entered into a clinical trial collaboration and supply agreement for the combination therapies of sintilimab...
JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Carteyva® (relma-cel, targeting CD19) was approved by the Macao Special Administrative Region Government's Drug Regulatory Authority. This marks the first overseas market...
Mediaseek’s Proprietary Neurofeedback Engine “Alpha Switch” and Its Smartphone Application Mentioned in International Journal
- Engine and App Used in Research Paper on Chronic Low Back Pain Treatment at Pain Center of Chiba University Hospital Published in "Scientific Reports" - TOKYO, Sept. 21, 2022 /PRNewswire/ -- Mediaseek, Inc. (hereinafter referred to as "Mediaseek") based in Tokyo is pleased to announce that a research article on the treatment of nonspecific chronic low back pain, conducted by the...
SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients
COPENHAGEN, Denmark, Jan. 25, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the company's first development candidate targeting E. coli in patients with hematological malignancy at risk of neutropenia. This announcement comes only a few weeks after the FDA approved the Investigational New Drug (IND) Application paving the way initiating the first clinical trial in humans. "At SNIPR BIOME, we are...
BioFlag Showcases Innovative Probiotic Solutions at Vitafoods Europe 2025
BARCELONA, Spain, May 20, 2025 /PRNewswire/ -- BIOFLAG CO.,LTD.(Bioflag), a leading probiotic enterprise located in China, proudly unveiled its scientifically validated functional probiotic solutions at Vitafoods Europe 2025, drawing high attention from global media. At the event, BioFlag highlighted its cutting-edge products, including clinically-proven probiotic strains and finished probiotic products targeting...
Sisram Medical Ltd. to Announce Full Year 2022 Financial Results on March 21, 2023
Conference call to be held on March 22, 2023, at 8:00 a.m. Eastern Time HONG KONG, March 17, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including Energy Based Devices,...
I-Mab Announces Upcoming Participation at October Conferences
SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October. Details of the conferences are as follows: J.P. Morgan Global Healthcare Conference One-on-one and...
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Pharma China Co., Ltd. ("Chugai Pharma China"). The agreement will allow 111 and Chugai Pharma China to work...
